Craig Authement1, Joshua Samuels2, Joyce P Samuel1. 1. Division of Pediatric Nephrology and Hypertension, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin St, MSB 3.502, Houston, TX, 77030, USA. 2. Division of Pediatric Nephrology and Hypertension, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin St, MSB 3.502, Houston, TX, 77030, USA. Joshua.A.Samuels@uth.tmc.edu.
Abstract
PURPOSE OF REVIEW: To review target organ outcomes and current pharmacologic treatment options for children and adolescents with hypertension. RECENT FINDINGS: There is an increased prevalence of pediatric hypertension. Following the 2017 AAP clinical practice guidelines, there is a growing body of literature illustrating the association between pediatric hypertension and end organ damage, though few studies looking at long-term outcomes. There is also new data to support the use of n-of-1 trials to identify the best antihypertensive therapy for an individual. Pediatric hypertension is increasing in prevalence and is associated with end organ damage. Treatment of hypertensive children has been shown to reverse end organ damage. Due to the lack of large, randomized trials assessing antihypertensive classes against one another, n-of-1 studies may serve as a viable and safe option to optimize patient care.
PURPOSE OF REVIEW: To review target organ outcomes and current pharmacologic treatment options for children and adolescents with hypertension. RECENT FINDINGS: There is an increased prevalence of pediatric hypertension. Following the 2017 AAP clinical practice guidelines, there is a growing body of literature illustrating the association between pediatric hypertension and end organ damage, though few studies looking at long-term outcomes. There is also new data to support the use of n-of-1 trials to identify the best antihypertensive therapy for an individual. Pediatric hypertension is increasing in prevalence and is associated with end organ damage. Treatment of hypertensive children has been shown to reverse end organ damage. Due to the lack of large, randomized trials assessing antihypertensive classes against one another, n-of-1 studies may serve as a viable and safe option to optimize patient care.
Authors: Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder Journal: Am J Med Date: 2003-07 Impact factor: 4.965
Authors: Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel Journal: Lancet Date: 2002-03-23 Impact factor: 79.321
Authors: Paolo Verdecchia; Fabio Angeli; Claudia Borgioni; Roberto Gattobigio; Gianni de Simone; Richard B Devereux; Carlo Porcellati Journal: Am J Hypertens Date: 2003-11 Impact factor: 2.689
Authors: Alex H Krist; Karina W Davidson; Carol M Mangione; Michael J Barry; Michael Cabana; Aaron B Caughey; Katrina Donahue; Chyke A Doubeni; John W Epling; Martha Kubik; Gbenga Ogedegbe; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2020-11-10 Impact factor: 56.272